Yüklüyor......
Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
The FDA-approved anti-androgen Enzalutamide (Enz) has been used successfully as the last line therapy to extend castration-resistant prostate cancer (CRPC) patients’ survival by an extra 4.8 months. However, CRPC patients eventually develop Enz-resistance that may involve the induction of the androg...
Kaydedildi:
| Yayımlandı: | Cell Death Dis |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7606511/ https://ncbi.nlm.nih.gov/pubmed/33139720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-02970-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|